U.S. Nasal Splints Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Nasal Splints
- ✓Market Size 2024: USD 142 million
- ✓Market Size 2032: USD 205 million
- ✓CAGR: 4.7%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Federal Contracts Lock Volume: Importers and domestic splint suppliers should submit Federal Supply Schedule 65 II A offers to the VA National Acquisition Center within six months. Multi-year federal contracts provide predictable volume to absorb tariff exposure and ethylene oxide abatement costs.
Nasal Splints in the U.S.: Market Overview
The U.S. nasal splints market is valued at an estimated USD 142 million in 2024 and is forecast to reach USD 205 million by 2032, tracking steady volumes of septoplasty, rhinoplasty and endoscopic sinus surgery. Silicone and polymer splints dominate, supplied chiefly by Medtronic through its Xomed ENT franchise and by Stryker's ENT portfolio. Hospitals buy most units through group purchasing organisations such as Vizient and Premier, while ambulatory surgery centres purchase directly from distributors. Manufacturers drive material innovation, whereas government sets the reimbursement, clearance and procurement conditions that define the market's shape.
Government has been the dominant force in shaping demand rather than in supplying product. The FDA regulates nasal splints as ear, nose and throat devices under 21 CFR Part 874, and most are cleared through the 510(k) pathway administered by the Center for Devices and Radiological Health. Medicare's Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment rules determine whether procedures requiring splints are reimbursed, which in turn sets procedure volume. Private manufacturers have led on material science, particularly self-expanding silicone designs that reduce post-operative discomfort.
Policy-Driven Growth for Nasal Splints in the U.S.
Medicare payment policy is the first mechanism. CPT 30520 for septoplasty and CPT 30420 for rhinoplasty are payable in hospital outpatient and ambulatory surgery settings under annual CMS rules, and every reimbursed procedure requires a splint or packing as part of post-operative care. Each annual OPPS and ASC final rule that preserves payment for these codes sustains procedure volume and therefore splint consumption. Growth follows directly from reimbursement stability, because hospitals and surgery centres schedule procedures only where payment is secured.
The second mechanism is federal procurement. The Department of Veterans Affairs buys medical supplies through Federal Supply Schedule 65 II A, administered by the VA National Acquisition Center, and the Defense Health Agency purchases through comparable contracting vehicles for TRICARE military treatment facilities. These standing contracts give suppliers predictable multi-year demand. The third mechanism is the Hospital Price Transparency rule under 45 CFR Part 180, which requires hospitals to publish negotiated charges and pushes purchasing toward standardised, lower-cost splint products.
Regulatory Barriers and Compliance Costs in the U.S.
FDA premarket clearance is the primary barrier. A 510(k) submission reviewed by CDRH carries a 90 FDA-day performance goal under MDUFA, but total time from pre-submission to clearance commonly runs six to twelve months once additional information requests are included. Manufacturers must also register and list devices under 21 CFR Part 807 and comply with the Quality Management System Regulation under 21 CFR Part 820. Compliance preparation for these requirements typically costs small suppliers a substantial share of annual regulatory budgets.
Sterilisation is the second barrier. Ethylene oxide remains the dominant method for sterilising silicone and polymer splints, and EPA's commercial sterilizer standards under 40 CFR Part 63 Subpart O impose tighter emission limits with compliance deadlines phased through 2026 and 2027. Sterilisers in urban areas face the highest abatement costs, and contract sterilisation agreements pass those costs to device makers. A third layer arrives through trade policy: Commerce initiated a Section 232 investigation into imported medical devices in September 2025, creating a live risk of new duties on finished splints and imported components.
Policy-Created Opportunities in the U.S.
Federal procurement offers the clearest opening for domestic suppliers. The VA and TRICARE systems prioritise contracted suppliers with validated quality systems and stable domestic supply, which rewards manufacturers that qualify under the QMSR before its February 2, 2026 effective date. Suppliers that secure Federal Supply Schedule listings gain multi-year volume that offsets the regulatory investment required for FDA compliance. Onshore production and sterilisation also position these firms favourably against imported products exposed to Section 232 duties.
The second opportunity lies in ambulatory surgery centre expansion. CMS adds procedures to the ASC covered list through its annual rulemaking, and ENT procedures are migrating from hospital outpatient departments into lower-cost settings. Suppliers offering standardised, single-use silicone splints packaged for ASC workflows capture this shift, particularly where distribution bypasses hospital group purchasing contracts. Ambulatory-ready packaging and validated sterilisation claims become decisive selection criteria in these settings.
Nasal Splints in the U.S. at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 142 million |
| Market Size 2032 | USD 205 million |
| Growth Rate (CAGR) | 4.7% |
| Most Critical Decision Factor | Medicare reimbursement status of covered ENT procedures |
| Largest Region | South Region (Census Bureau) |
| Competitive Structure | Oligopolistic, led by Medtronic and Stryker |
Leading Market Participants
- Medtronic
- Stryker
- Johnson & Johnson MedTech
- Smith & Nephew
- Karl Storz
- Olympus
- Teleflex
- Cardinal Health
- Medline Industries
- B. Braun Medical
Regulatory and Policy Environment for Nasal Splints in the U.S.
The Federal Food, Drug, and Cosmetic Act, as amended by the Medical Device Amendments of 1976, sets the legal framework, with nasal splints classified under 21 CFR Part 874 and most cleared through 510(k) premarket notification. The FDA's Center for Devices and Radiological Health administers clearance, while the Medical Device User Fee Amendments (MDUFA V) fund review staffing through fiscal year 2027. Manufacturers must maintain establishment registration under 21 CFR Part 807, unique device identification under 21 CFR Part 801, and adverse event reporting under 21 CFR Part 803.
Upcoming changes cluster around three dates. The Quality Management System Regulation, amending 21 CFR Part 820, takes effect on February 2, 2026, harmonising U.S. requirements with ISO 13485:2016. MDUFA V expires on September 30, 2027, triggering MDUFA VI negotiations between FDA and industry during 2026. Compared with regional peers, the U.S. clearance pathway is faster than the EU Medical Device Regulation 2017/745, whose transitional deadlines for many sterile devices extend into 2028, but less uniform than Canada's class-based licensing under SOR/98-282.
Long-Term Policy Outlook for Nasal Splints in the U.S.
By 2032, the most consequential policy shift will be the reordering of procurement rules. Hospital price transparency enforcement under 45 CFR Part 180 and the Section 232 medical device investigation will push purchasing toward domestically manufactured and sterilised product, raising the share of U.S.-sourced splints. MDUFA VI negotiations will shape review timelines for low-risk ENT devices, directly affecting the cost of bringing new silicone designs to market.
CMS will continue expanding the ASC covered procedures list annually, moving septoplasty and related sinus procedures into lower-cost settings. This shift reduces hospital demand for premium splints, rewards suppliers with standardised ASC-ready product, and moves distribution away from hospital group purchasing toward specialty ENT distributors. Ethylene oxide abatement under EPA's Subpart O will keep sterilisation prices elevated through the decade, favouring suppliers that have invested in onshore sterilisation or validated alternative methods such as vaporised hydrogen peroxide.
Frequently Asked Questions
Market Segmentation
- Silicone Nasal Splints
- Doyle-Type Splints
- Absorbable Nasal Packing
- Non-Absorbable Nasal Packing
- Self-Expanding Polymer Splints
- Hospitals
- Ambulatory Surgery Centres
- Physician Offices
- Veterans Affairs Facilities
- Military Treatment Facilities
- Group Purchasing Organisations
- Direct Hospital Procurement
- Specialty ENT Distributors
- Federal Supply Schedule Contracts
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.